These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


184 related items for PubMed ID: 10372838

  • 1. Medical management of secondary hyperparathyroidism in uremia.
    Drüeke TB.
    Am J Med Sci; 1999 Jun; 317(6):383-9. PubMed ID: 10372838
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M, Ritz E.
    Nephrol Dial Transplant; 2000 Nov; 15 Suppl 5():18-24. PubMed ID: 11073270
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA, DiBartola SP, Chew DJ, Nagode LA, Schenck PA, Rajala-Schultz PJ, Drost WT.
    J Vet Intern Med; 2006 Nov; 20(6):1307-13. PubMed ID: 17186842
    [Abstract] [Full Text] [Related]

  • 8. New therapies for uremic secondary hyperparathyroidism.
    Torres PU, Prié D, Beck L, Friedlander G.
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [Abstract] [Full Text] [Related]

  • 9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP.
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [Abstract] [Full Text] [Related]

  • 10. Parathyroid growth and suppression in renal failure.
    Lewin E, Huan J, Olgaard K.
    Semin Dial; 2006 Feb; 19(3):238-45. PubMed ID: 16689976
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 15. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
    Zella JB, Plum LA, Plowchalk DR, Potochoiba M, Clagett-Dame M, DeLuca HF.
    Am J Nephrol; 2014 Feb; 39(6):476-83. PubMed ID: 24854296
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Secondary hyperparathyroidism in renal insufficiency. Prevention and therapy].
    Malluche HH, Ritz E.
    MMW Munch Med Wochenschr; 1976 Jan 30; 118(5):129-30. PubMed ID: 814442
    [No Abstract] [Full Text] [Related]

  • 19. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients.
    Shiizaki K, Negi S, Mizobuchi M, Hatamura I, Narukawa N, Sakaguchi T, Kitabata Y, Sumikado S, Akizawa T.
    Nephrol Dial Transplant; 2003 Jun 30; 18 Suppl 3():iii42-6. PubMed ID: 12771299
    [Abstract] [Full Text] [Related]

  • 20. Non-suppressible secondary hyperparathyroidism in chronic progressive renal disease.
    Slatopolsky E, Rutherford WE, Hoffsten PE, Elkan IO, Butcher HR, Bricker NS.
    Kidney Int; 1972 Jun 30; 1(1):38-46. PubMed ID: 5075944
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.